Alzheon reports Phase 3 win with an Alzheimer’s treatment targeted at high-risk genetic carriers
Alzheon announced a peer-reviewed publication presenting integrated analyses of Phase 3 APOLLOE4 and Phase 2 data that, according to the company, showed early and sustained reductions in plasma p-tau217 and the p-tau217/Aβ42 ratio in APOE4 carriers with early Alzheimer’s disease. The company claims
<p>Alzheon announced a peer-reviewed publication presenting integrated analyses of Phase 3 APOLLOE4 and Phase 2 data that, according to the company, showed early and sustained reductions in plasma p-tau217 and the p-tau217/Aβ42 ratio in APOE4 carriers with early Alzheimer’s disease. The company claims </p>